The combined targeting of EGFR and KRAS (G12C) is highly effective in CRC cells, PDO and PDX, suggesting a new therapeutic strategy to treat patients with KRAS (G12C)-mutated CRC [101]. This evidence concerns the gene KRAS and colorectal carcinoma.